The three drugs were indicated for the treatment of adult patients with relapsed or refractory MM who had received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 mAb [165,166]. Here, CD38 is linked to Miyoshi myopathy.